Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25793
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuang, Qiutong-
dc.contributor.authorJacquelot, Nicolas-
dc.contributor.authorPreaudet, Adele-
dc.contributor.authorHediyeh-Zadeh, Soroor-
dc.contributor.authorSouza-Fonseca-Guimaraes, Fernando-
dc.contributor.authorMcKenzie, Andrew N J-
dc.contributor.authorHansbro, Philip M-
dc.contributor.authorDavis, Melissa J-
dc.contributor.authorMielke, Lisa A-
dc.contributor.authorPutoczki, Tracy L-
dc.contributor.authorBelz, Gabrielle T-
dc.date2021-02-01-
dc.date.accessioned2021-02-07T23:58:05Z-
dc.date.available2021-02-07T23:58:05Z-
dc.date.issued2021-02-01-
dc.identifier.citationCancers 2021; 13(3): 559en
dc.identifier.issn2072-6694
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25793-
dc.description.abstractChronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches.en
dc.language.isoeng
dc.subjectIL-13en
dc.subjectIL-5en
dc.subjectILC2en
dc.subjectcolitis-associated canceren
dc.subjectcolon canceren
dc.subjectinflammationen
dc.titleType 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancersen
dc.identifier.affiliationWalter and Eliza Hall Institute of Medical Research, Parkville, Melbourne 3052, Australiaen
dc.identifier.affiliationDepartment of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, Australiaen
dc.identifier.affiliationThe University of Queensland Diamantina Institute, 37 Kent Street, Woolloongabba, Brisbane 4102, Australiaen
dc.identifier.affiliationMedical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UKen
dc.identifier.affiliationCenter for Inflammation, Centenary Institute and the School of Life Sciences, University of Technology Sydney, Sydney 2050, Australiaen
dc.identifier.affiliationDepartment of Clinical Pathology, University of Melbourne, Parkville, Melbourne 3010, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationLa Trobe University School of Cancer Medicine, Heidelberg 3084, Australiaen
dc.identifier.doi10.3390/cancers13030559en
dc.type.contentTexten
dc.identifier.orcid0000-0003-0282-1892en
dc.identifier.orcid0000-0002-2037-8946en
dc.identifier.orcid0000-0002-9522-9320en
dc.identifier.orcid0000-0003-1639-4932en
dc.identifier.pubmedid33535624
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.